We are CellEctric

Our Mission

CellEctric is building the bridge between electrodynamics and biology. We believe that electrodynamic cell manipulation will make routine life science applications faster, easier, and more precise.

By combining cutting-edge developments in material science, electrical engineering, and biotechnology, CellEctric is committed to shaping a better, healthier future for all.

Founded in early 2021, we are currently developing a platform that transforms complex samples into simple, single-population solutions. Our current showcase is the isolation of viable bacteria from human samples toward greatly accelerated sepsis diagnosis. The future pipeline is filled with proof-of-concept applications such as the isolation of leukocytes from human whole-blood, toward a customizable platform that separates increasingly similar mammalian cell populations at high throughput.

Fast, automated, and selective.

Our Journey

The initial idea and proof-of-principle of our novel strategy for sample preparation toward accelerating sepsis diagnosis was awarded with the Falling Walls Young Innovator Award in 2013. The bio-electrodynamic technology concept received a Young Investigator Award at the 2015 World Congress on Electroporation. Technology maturation was enabled through internal financing by Austria’s biggest research institute, the AIT Austrian Institute of Technology GmbH, securing patents for several further applications of the technology.

The translation of research toward prototype development was funded by the FFG Spin-off Fellowship and the AWS PreSeed program. Current funding is secured via the FFG Basisprogramm along with private equity investments lead by IST Cube. In 2021, CellEctric had its business plan awarded in the annual i2B competition and won the Austrian Phönix Gründerpreis. With sepsis as a first business case, CellEctric aims to become the world leader in electrodynamic applications for biotechnology and bioelectric medicine.